Dr. Momina  Qazi  Md image

Dr. Momina Qazi Md

30 E Apple St Suite 6250
Dayton OH 45409
937 088-8394
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 35.088433
NPI: 1669667226
Taxonomy Codes:

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


None Found


Immunotherapy for allergies and asthma: present and future. - Current opinion in pharmacology
Allergen immunotherapy (IT) is a proven approach for treating allergic rhinitis and allergic asthma that has been practiced since 1911 and has undergone significant development in the past two decades. As currently practiced, IT involves subcutaneous or sublingual administration of allergens, both methods of which have been extensively investigated. In addition to allergen IT, a number of additional nonspecific IT approaches are being used or are in phase II/phase III clinical trials, which may be available in clinics within the next one to three years. Such therapies include anti-IgE antibodies and the soluble IL-4 receptor. Other experimental IT approaches are at the preclinical research stage and may proceed to clinical trials and the clinic within the next five to ten years. This review discusses the pros and cons of recent developments in both currently practiced and experimental IT approaches.Copyright 2010 Elsevier Ltd. All rights reserved.
Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. - Expert review of clinical immunology
Ecallantide (Kalbitor, Dyax Corporation) is a highly specific recombinant plasma kallikrein inhibitor developed for treatment of hereditary angioedema (HAE). Advantages of this agent over plasma-derived treatments are that it poses no risk of viral contamination, is highly selective, has a quick onset of action and can be administered subcutaneously. In clinical trials, ecallantide appears to be a safe and effective drug useful for the treatment of HAE patients suffering from an acute attack. Ecallantide was found to be superior compared with placebo in relieving symptoms, decreasing the severity of attacks and shortening the duration of attacks. The primary safety concern appears to be related to hypersensitivity reactions. Phase IV postmarketing surveillance studies to monitor the incidence of these reactions will be implemented by the company now that the drug has been US FDA approved.

Map & Directions

30 E Apple St Suite 6250 Dayton, OH 45409
View Directions In Google Maps

Nearby Doctors

30 E Apple St Suite 2200
Dayton, OH 45409
937 082-2091
30 E Apple St Suite 6250
Dayton, OH 45409
937 088-8000
1 Wyoming St
Dayton, OH 45409
937 088-8394
1 Wyoming St Ste. 3130
Dayton, OH 45409
937 085-5250
30 E Apple St Suite 6250
Dayton, OH 45409
937 088-8394
122 Wyoming St
Dayton, OH 45409
937 234-4461
1250 W Dorothy Ln Ste 208
Kettering, OH 45409
937 989-9241
3025 Governors Place Blvd
Dayton, OH 45409
937 935-5567
1520 S Main St # 2
Dayton, OH 45409
937 615-5815